Inke Sabine Feder

Title: Inke Sabine Feder: Innovator in Breast Cancer Prognosis

Introduction

Inke Sabine Feder is a prominent inventor based in Cologne, Germany. She has made significant contributions to the field of medical technology, particularly in breast cancer prognosis. With a total of 3 patents, her work focuses on improving the accuracy of disease outcome predictions for breast cancer patients.

Latest Patents

One of her latest patents is a method for breast cancer recurrence prediction under endocrine treatment. This invention relates to methods, kits, and systems designed for the prognosis of breast cancer outcomes. The method involves determining RNA expression levels of at least two of nine specific genes in a tumor sample. These genes include UBE2C, BIRC5, RACGAP1, DHCR7, STC2, AZGP1, RBBP8, IL6ST, and MGP. The expression level values are mathematically combined to yield a score indicative of the patient's prognosis.

Career Highlights

Inke has worked with notable companies in the medical field, including Myriad International GmbH and Sividon Diagnostics GmbH. Her experience in these organizations has contributed to her expertise in developing innovative solutions for cancer prognosis.

Collaborations

Inke has collaborated with professionals such as Mareike Dartmann and Mathias Gehrmann, enhancing her research and development efforts in the medical technology sector.

Conclusion

Inke Sabine Feder's work in breast cancer prognosis exemplifies the impact of innovation in healthcare. Her patents and collaborations reflect her commitment to improving patient outcomes through advanced medical technologies.